Drug Trial Radar · NCT01819727
An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165
Last checked: Nov 20, 2026Latest source record: Feb 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
261
Actual
Start
May 2013
Primary completion
Nov 25, 2015
Study completion Nov 25, 2015
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- Mar 28, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The BMN 165 clinical development program has been designed to demonstrate the safety and efficacy of BMN 165 in reducing blood Phe concentrations in patients 18 to 70 years old with hyperphenylalaninemia due to PKU. Study BMN 165-301 is a Phase 3, open-label, randomized study designed to further characterize the safety of BMN 165 during two induction, titration, and maintenance dose regimens in adults with PKU who have not had previous exposure to BMN 165 (naive). Subjects will be randomized (1:1) to titrate up to one of two dose regimens. Other key features of this study are the dose regimens chosen for induction and titration; the study duration; self administration of study drug; and the chosen tertiary objectives.
Conditions
- Phenylketonuria
Interventions
BMN 165Drug
After informed consent, eligible subjects will be randomized (1:1) to titrate up to one of two dose regimens: 20 mg/day or 40 mg/day. All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction). After the Induction Period, subjects will enter the Titration Period (Weeks 5 up to 34) where they will increase their weekly BMN 165 dose to a daily dose regimen of 20 mg/day or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the amount of time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 30 weeks (accounts for dose reduction or interruption due to AEs). Subjects will stop titration once they have achieved either the 20 mg/day or 40 mg/day dose regimen. The majority of subjects will maintain the 20 or 40 mg/day dose regimen for at least an additional 2 weeks until a minimum of approximately 26 weeks or a maximum of 36 weeks in the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Hypersensitivity Adverse ReactionTime frame: baseline and 36 weeks
Locations
31 sites in 1 country. Site status is shown where the registry gives one.
University of California, Altman Clinical and Translational Research Institute
La Jolla, California
UCSF Benioff Children's Hospital Oakland
Oakland, California
The Children's Hospital Colorado
Aurora, Colorado
University of Florida Clinical Research Center
Gainesville, Florida
University of Miami Health System
Miami, Florida
University of South Florida
Tampa, Florida
Emory Universty
Decatur, Georgia
Ann and Robert H Lurie Children's Hospital of Chicago
Chicago, Illinois
Riley Children's Hospital
Indianapolis, Indiana
University of Kentucky Medical Center
Lexington, Kentucky
Weisskopf Child Evaluation Center / University of Louisville
Louisville, Kentucky
Boston Children's Hospital
Boston, Massachusetts
Wayne State University
Detroit, Michigan
University of Missouri
Columbia, Missouri
Washington University Center for Applied Research Sciences
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
Cooper Health Systems
Camden, New Jersey
Atlantic Health System - Morristown Medical Center
Morristown, New Jersey
Albany Medical College
Albany, New York
Icahn School of Medicine at Mount Sinai Medical Center
New York, New York
University of Rochester
Rochester, New York
University Hospital Cleveland, Case Medical Center
Cleveland, Ohio
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Oregon Health & Science University
Portland, Oregon
St. Christopher's Hospital for Children
Philadelphia, Pennsylvania
Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
University of Texas Health Science at Houston
Houston, Texas
University of Utah
Salt Lake City, Utah
University of Washington Medical Center
Seattle, Washington
Children's Hospital of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.